US Federal 2025-2026 Regular Session

US Federal House Bill HB6320

Introduced
 
Introduced
11/28/25  

Caption

Improving Medicaid Precision and Cancer Test Act of 2025

Summary

HB6320, titled the Improving Medicaid Precision and Cancer Test Act of 2025, would amend Title XIX of the Social Security Act to require Medicaid coverage of lung cancer biomarker testing. The bill adds lung cancer biomarker testing as a covered Medicaid benefit and makes conforming changes to the statute governing Medicaid state plan requirements and covered services. The legislation specifies that the new coverage requirement would take effect beginning January 1, 2027. In practical terms, this would require state Medicaid programs to include coverage for biomarker testing used in diagnosing or guiding treatment for lung cancer, which is often used to identify targeted therapies and other precision medicine options.

Impact

The bill would change federal Medicaid law by adding lung cancer biomarker testing to the list of mandatory covered services under Title XIX. It would affect state Medicaid programs by requiring them to cover this testing for eligible beneficiaries once the effective date arrives, and it would also update related statutory references to ensure the new benefit is incorporated into Medicaid coverage rules, including managed care-related provisions.

Sentiment

There is no recorded committee debate or vote history in the provided materials, so no direct legislative sentiment can be measured from hearings or roll calls. Based on the bill’s bipartisan sponsorship and its health-care access focus, the measure appears to be framed as a patient-access and cancer-care improvement bill rather than a controversial policy change.

Contention

No specific points of contention are documented in the available transcript or voting record. Potential areas of debate, if the bill advances, could include the cost to state Medicaid programs, administrative implementation, and whether mandatory coverage should be set at the federal level versus left to state discretion. At present, however, the provided materials do not identify any named opponents or disputed provisions.

Companion Bills

No companion bills found.

Previously Filed As

US HB6321

Lung Cancer Medicare Access to Precise Testing Act

US LB253

Provide for insurance and medicaid coverage of biomarker testing

US HB4543

Medicaid Breast Cancer Access to Treatment Act

US HB1620

Finn Sawyer Access to Cancer Testing Act

US HB3954

Improving Access to Medicare Coverage Act of 2025

US HB1406

Lung Cancer Screening and Prevention Act of 2025

US HB6863

CAT Act of 2025 Centers for Medicare & Medicaid Services Auditor Transparency Act of 2025

US HB2472

INFANTS Act of 2025 Improving Newborns’ Food and Nutrition Testing Safety Act of 2025

US HB6178

Increasing Access to Lung Cancer Screening Act

US HB8

Require health plan and Medicaid coverage of biomarker testing

Similar Bills

No similar bills found.